IGSF8 (F6M8L) Rabbit Monoclonal Antibody #91585

Immunoglobulin superfamily member 8 (IGSF8), also known as CD316 or EWI-2, is a type-I transmembrane protein that belongs to the immunoglobulin superfamily (1-3). IGSF8 was initially characterized as a binding partner with CD9 and CD81, regulating vesicle trafficking (1). Recent work has focused on the role of IGSF8 in various cellular functions, such as cell motility, cell adhesion, innate immunity, neural development, and tumor biology (1-4). IGSF8 can act as a checkpoint for innate immunity by inhibiting natural killer (NK) cell response in cancer immunotherapy (3,7). Curiously, IGSF8 can exhibit contrasting roles in tumors, acting either as a tumor suppressor or an oncoprotein. In certain solid tumor cancers, such as lung, skin, prostate, and brain, IGSF8 suppresses tumor progression by inhibiting proliferation and metastasis (2,6-7). In contrast, in hematological malignancies like leukemias, IGSF8 sustains cancer cell stemness, which promotes therapy resistance and disease progression (6,8,9). IGSF8 has recently emerged as an innate immune checkpoint molecule in the tumor microenvironment (TME) (6). By inhibiting NK cell-mediated interactions with immune inhibitory receptors, IGSF8 reduces cytotoxicity, contributing to immune evasion in immunologically “cold” tumors, making the protein an interesting therapeutic target (6-8). test